

Index

a

- ABC. *see* ATP-binding cassette (ABC)
- ABC transporters, 12, 107
- effects on drug disposition, 112
 - mutations, 113
 - neurological disorders, role in, 180–181
 - PET imaging, 181–183
 - PET tracers
 - applications, 184–185
 - designing, challenges in, 184
 - pharmacochaperones and, 113, 114
 - proteins, 7
 - role of, 108
 - superfamily, 2
 - from targets to antitargets, 111–113
- absorption, disposition, metabolism and excretion (ADME), 253
- SLC transporters, importance in, 253
- acetylcholine, 41
- ADME. *see* absorption, disposition, metabolism and excretion (ADME)
- age-related insensitivity, 40
- alanine-serine-cysteine transporter 1 (ASCT1), 260
- alanine-serine-cysteine transporter 2 (ASCT2), 253, 260
- Alisma orientalis*, 212, 213
- allosteric effect
- citalopram, 29
 - escitalopram, 28
- allosteric mechanism, 30
- allosteric serotonin reuptake inhibitors (ASRIs), 26
- allosteric serotonin transporter modulators, 28, 30
- allosteric site, on serotonin transporter
- localization of, 27, 28
 - structure-activity relationships at, 28–30
- alzheimer's disease, 180
- amidotransferases, 263
- γ -glutamyl transpeptidase, 263
- amine hypothesis, 21
- amino acid/polyamine-organocation superfamily, 16
- amino acid/polyamine/organocation transporter (APC), 262
- amino acid transporters, 254
- γ -aminobutyric acid (GABA), 24, 69
- neurotransmission, 85
 - signaling, 73, 85
- aminophospholipid, 204
- ammonia channel transporter (Amt) family, 7
- amyloid precursor protein (APP), 180
- anaesthetics, 1
- anion exchanger, 144
- anoctamin 1 (ANO1), 231, 233, 234
- activators of, 240
 - biophysical properties of, 234, 235
 - calcium activated chloride channel, 232
 - and cancer, 236–238
 - characterization of, 232
 - as contributor to renal cyst growth, 245
 - cystic fibrosis-related diabetes (CFRD), 232, 245
 - discovery of, 232, 233
 - effect on motility of human cancer cells, 237
 - expression and physiological role of, 235, 236
 - gene coding for, 236
 - in GIST, 231
 - inhibition, during a type I asthma attack, 232
 - inhibitors, structures of, 239
 - natural products, 240, 241
 - as passenger event, 236
 - pharmacological targeting of, 238
 - potential risks, of therapeutic intervention, 245, 246
 - small-molecule inhibitors of, 238–240

- structure of, 234, 239
 - therapeutic paradigms for, 246
 - as therapeutic target, 241
 - for tumor growth in breast and head and neck cancers, 232
 - anthranilic acid, 186, 187
 - antiarrhythmic drugs, 1
 - anticancer drugs, 109, 131
 - antidepressant, 22
 - drug, 22, 24, 56
 - – nomenclature, 22–24
 - possible approach to a new classification of, 23
 - SNRIs, 32
 - therapies, 22
 - antidiabetic drug
 - metformin, 253
 - antiepileptic drug, 180
 - antihypertensive drugs, 1
 - antineoplastic agents, 17
 - antiporter, 5
 - APC. *see* amino acid/polyamine/organocation transporter (APC)
 - apical (canalicular) membrane, 199
 - approved drugs, and targeted transport proteins, 14
 - Aquifex aeolicus*, 55
 - N*-arachidonyl-glycine (NAGly), 94
 - ASCT1. *see* alanine-serine-cysteine transporter 1 (ASCT1)
 - ASCT2. *see* alanine-serine-cysteine transporter 2 (ASCT2)
 - asthma, 231, 242
 - atherosclerosis, 135
 - atomoxetine, 30
 - ATPases, 7
 - ATP-binding cassette (ABC), 179
 - family, 5
 - proteins, 7, 10
 - transporters, 119, 200 (*see also* ABC transporters)
 - – basolateral, 119
 - – ABCC3, 136
 - – ABCC4, 138
 - – canalicular, 119, 122
 - – ABCB1, 126
 - – ABCB4, 131
 - – ABCB11, 122
 - – ABCC2, 126
 - – ABCG2, 133
 - – ABCG5/8, 131
 - ATP-dependent xenotoxin transport pump, 107
 - Atractylodes macrocephala*, 212, 213
 - attention deficit hyperactivity disorder (ADHD), 30
 - audiogenic seizure (AGS), 86
 - autoradiography, 40
- b**
- BA homeostasis, 141
 - BA-mediated activation, 202
 - of FXR, 201
 - β -amyloid (A β) clearance, 180
 - BAs. *see* bile acids (BAs)
 - basolateral membrane, 199
 - basolateral transport proteins, 199
 - BBB. *see* blood-brain barrier (BBB)
 - BCRP. *see* breast cancer resistance protein (BCRP)
 - BCS. *see* Biopharmaceutics Classification System (BCS)
 - BDL. *see* bile duct ligated (BDL)
 - benign recurrent intrahepatic cholestasis (BRIC), 200
 - benzimidazole derivatives, 218, 219
 - betaine/GABA transporter 1 (BGT1), 74
 - BGT1. *see* betaine/GABA transporter 1 (BGT1)
 - bile acids (BAs), 113, 119, 201, 305
 - enterohepatic cycle, 199
 - bile duct epithelium, 142
 - bile duct ligated (BDL), 137
 - bile salt export pump (BSEP or ABCB11), 121, 200
 - bilirubin, 126–128
 - conjugated, 144
 - unconjugated, 129, 280, 285
 - bioactivity data counts, 15
 - Biopharmaceutics Classification System (BCS), 111
 - BLAST search, 4
 - blood-brain barrier (BBB), 112, 179, 263
 - botulinum neurotoxin A, 12
 - brain
 - capillary endothelial cells, 179
 - pharmacological sanctuary, role as, 180
 - breast cancer resistance protein (BCRP), 108
 - breast cancers, 232
 - Brintellix[®], 38
 - British Pharmacological Society (BPS), 5
 - BSEP. *see* bile salt export pump (BSEP)
 - BSEP expression, mediated by CDCA, 203
 - BSEP gene, 203
 - Byler disease, 204

c

- CA. *see* cholic acid (CA)
- Ca²⁺/calmodulin-dependent protein kinase II α (α CaMKII), 58
- Caco-2 cell, 189
- cafestol, 203
- calcium channel blockers, 109
- calmodulin, 235
- camptothecin, 189
- canalicular membrane, 202
- canalicular transport protein BSEP (ABCB11), 203
- cancer, 107, 231, 243–245
- cancer cells, 131
- cancer development
- SLC transporters in, 263
- cancer metabolism
- amino acid transporters in, 253
 - solute carriers in, 253–255
 - targets, 260–263
 - – ASCT2, 260–262
 - – LAT-1, 262–263
- cancer pathogenesis
- SLC transporters, role in, 253
- cancer-related transporters
- ASCT2, 264
 - LAT-1, 264
- cancer therapy, 15
- transporter targeting in, 263
- CAR. *see* constitutive androstane receptor (CAR)
- CARM-1 (coactivator-associated arginine (“R”) methyl transferase-1), 207
- cation-chloride cotransporter (CCC) family (SLC 12), 1
- CDCA. *see* chenodeoxycholic acid (CDCA)
- cell swelling, 125
- central nervous system (CNS)-targeted drugs, 180
- cerebral ABC transporters
- PET tracers, 185–191
 - – radiolabelled BCRP substrates, 189
 - – radiolabelled dual P-gp/BCRP substrates, 189–190
 - – radiolabelled MRP1 substrates, 190–191
 - – radiolabelled P-gp inhibitors, 187–189
 - – radiolabelled P-gp substrates, 185–187
- cerebrospinal fluid (CSF) biomarkers, 24
- CFRD. *see* cystic fibrosis-related diabetes (CFRD)
- CFTR. *see* cystic fibrosis transmembrane regulator (CFTR)
- channels of ChEMBL-16, 11
- ChEMBL classification, 2, 11
- ChEMBL-16, 5, 7
 - – transporter hierarchy, 5
 - ChEMBL-18, 5
 - ChEMBL-19, 12, 15
 - database, 5
- chemoconvulsants, 87
- chenodeoxycholic acid (CDCA), 121, 201
- chloride channel, 12
- chloride-independent transporters
- leucine transporter (LeuT), 77
- chloride (Cl⁻) ion, 231
- channel activation, 231
- cholangiocytes, 207
- cholehepatic shunt pathway, 207
- cholestasis, 119, 200, 205
- disorders, 201
- cholestasis of pregnancy (ICP), 123
- cholestatic diseases, 204
- cholestatic patients, 119
- clinical management of, 145
- cholesterol, 201
- lowering drug, 12
- cholic acid (CA), 121
- Cipraxel[®], 26
- cirrhosis, 113, 119, 130, 132, 210, 221, 298, 301
- citalopram, 26–30, 38
- c-Jun N-terminal kinase (JNK) pathways, 202
- cladograms, 15
- classified membrane transport proteins in IUPHAR/BPS, TCDB, and ChEMBL-16, overlap of, 11
- clinical PET studies, 40
- clinical trials, 15, 82, 94, 95, 126, 140, 144, 221, 240, 241, 243, 300
- clomipramine, 27, 56, 59
- cloxacillin, 203
- Clustal Omega, 16
- cocrystallization, 78
- cognitive dysfunction, 22
- combined SERT inhibitors
- and 5-HT_{1A} receptor antagonists, 37
- Commiphora mukul*, 211
- conicasterol E, 213, 214
- conjugated steroid metabolites, 204
- constipation, 15
- constitutive androstane receptor (CAR), 120, 121, 125
- contradictory classification in TCDB, IUPHAR/BPS, and ChEMBL-16, 7, 8
- coumestrol, 214, 215
- cyclic adenosine monophosphate (cAMP), 231
- cyclosporine A, 203

- Cymbalta[®], 32
 CYP7A1 expression, 219
 cystic fibrosis (CF), 113, 231, 241, 242
 – caused by, 241
 – mucus production, 232
 – treatment of, 242
 cystic fibrosis-related diabetes (CFRD), 245
 cystic fibrosis transmembrane conductance regulator (CFTR) protein, 12, 231
 cytokines, 128, 129, 131, 138, 202, 232, 242
 cytosolic calcium, 234
- d**
- Dalcipran[®], 32
 DAT (dopamine transporter), 22
 database database, 2
 12-*O*-deacetyl-12-*epi*-19-deoxy-21-hydroxyscalarin, 213
 dendritic cells, 139
Dendronephthya gigantean, 214
 depression, 21, 180
 – and antidepressant drugs, disease biology of, 24, 25
 desipramine, 28, 56
 diabetic nephropathy, 201
 12,24-diacetoxy-deoxyscalarin, 213
 diarrhea, 212, 213, 231, 232, 236, 242, 243, 246
 dietary supplementation, 136
 DILI. *see* drug-induced liver injury (DILI)
 dimethoxytetrahydroisoquinolinyethyl, 186, 187
 discrete distribution, 24
 DisGeNET, 15
 diterpene compound, 203
 diuretics, 1, 14
 DNA-binding domain, 205
 docking programs, 259, 260
 dopamine (DA) uptake, 31
Drosophila melanogaster, 56
 DrugBank, 1
 drug design
 – structure-based
 – – in silico methods for
 – – homology modeling, 256–259
 – – ligand prediction, 259–260
 – – transporter dynamics, 259
 drug development
 – small-molecule ligands, role in, 260
 drug discovery, 255
 – homology modeling, 255
 – – model building and assessment, 258
 – – model refinement, 258
 – – model validation, 258–259
 – – target–template alignment, 258
 – – template selection, 256–258
 – virtual screening, 255
 drug-induced alterations, 200
 drug-induced liver injury (DILI), 113
 drugs, pharmacokinetics of, 134
 drug targets, 69
 – in SLC classification, 15
 drug toxicity, 131
 drug transporters, 131
 – mutations in, 253
 drug–transport interactions, 200
 Dubin–Johnson syndrome, 113, 127, 137, 200
 duloxetine, 25, 32, 35
- e**
- EBI Web server, 16
 edivoxetine (LY2216684), 30, 31
 Effexor[®], 32
 EGFR. *see* epidermal growth factor receptor's (EGFR)
 endogenous modulator, 201
 enterocytes, 205
 enterohepatic circulation, 202
 Enzyme Commission (EC) classification, 2
 epidermal growth factor receptor's (EGFR), 190
 (-)-epigallocatechins-3-gallate (EGCG), 214, 215
 Epilepsy, 85
 – GABAergic system in, 85
 – GAT role in, 86
 epileptic brain tissue, 180
 erlotinib, 180, 190
 ER-8 response element, 205
 escitalopram, 25, 26
 – allosteric effect, 27
 – antagonistic effect on, 26
 – dissociation, 29
 – internalization induced by, 27
 – mutations in S2 pocket, 28
 – 1-naphthyl derivative of, 28
 ethynylestradiol, 138
 eukaryotic dopamine transporter, 72
 European Medicine Agency (EMA), 32
 extracellular neurotransmitter, 70
 ezetimibe, 12
- f**
- familial intrahepatic cholestasis 1 (FIC1), 204
 farnesol, 201
 Fexaramine and derivatives, 217
 fibrosis, 144, 210. *see also* Cystic fibrosis

- antifibrotic effects in a rat model of liver, 143
 - multiple FXR-mediated activities and, 210
 - PPAR γ agonist troglitazone decrease, 144
 - tetrachloride-induced, 143
 - Fisher rat thyroid (FRT) cell model, 239
 - fluoxetine, 26–28, 42
 - flvoxamine, 26
 - folding sensor, 58
 - fold recognition methods
 - HHPred, 257
 - Promals3D, 257
 - Fructus ligustri lucidi*, 212
 - F-type and V-type ATPases, 5
 - function vs. sequence similarity, 7
 - FXR-activated pathway, 207
 - FXR activity (EC₅₀, IC₅₀) of triterpene derivatives, 212
 - FXR α gene*, 207
 - FXR450 and derivatives, 217, 218
 - FXR and PXR receptors, 213
 - FXR gene knockout, 204
 - FXR ligands, 209
 - natural compounds and derivatives, 209
 - bile acids and derivatives, 209–211
 - guggulsterones, 211, 212
 - miscellaneous natural compounds and derivatives, 214, 215
 - sterols and polyhydroxylated sterol derivatives, 213, 214
 - triterpenes, 212, 213
 - from virtual screening campaigns, 220
 - FXR-mediated inhibition
 - OATP-C expression, 207
 - FXR-mediated mechanisms, 202
 - FXR null mice, 201
 - FXR/RXR α heterodimer complex, 203, 204
 - FXR/TGR5 agonist, 210
- g**
- GABA. *see* γ -aminobutyric acid (GABA)
 - GABA transporters (GAT), 70, 73–89
 - GABA uptake inhibitors
 - medicinal chemistry of, 78–85
 - GAT inhibitors, 86
 - therapeutic potential of, 85–89
 - animal models of anticonvulsant action, 86–87
 - GAT inhibitors and epilepsy, 87–89
 - role in epilepsy/anticonvulsive therapy, 85–86
 - therapeutic potential of GAT in the recovery of stroke, 89
 - localization of, 73
 - molecular pharmacology of, 73–78
 - transporter structure–function studies, 76–78
 - nomenclature of, 72
 - subtypes, 72, 75, 85
 - modeling of, 76
 - gallstone disease, 201
 - Ganoderma lucidum*, 212
 - gastrointestinal stromal tumor (GIST), 231
 - GAT. *see* GABA transporters (GAT)
 - GAT inhibitors, 73, 74
 - subtype-selective binding of, 77
 - GAT substrates, 74
 - GBM. *see* glioblastoma multiforme (GBM)
 - gefitinib, 180, 190
 - gene expression, 144
 - gene mutations, 133
 - GeneOntology, 11
 - gene promoters, 205
 - genetic and structural properties of FXR, 207–209
 - genetic polymorphism, 188
 - GIST. *see* gastrointestinal stromal tumor (GIST)
 - glibenclamide, 203, 282
 - glioblastoma multiforme (GBM), 260
 - glucocorticoid receptor (GR), 140
 - glucose homeostasis, 201
 - glutamate, 24, 41, 62, 77, 86, 90, 259, 261
 - glutathione, 204
 - Gly. *see* glycine (Gly)
 - glycine (Gly), 17, 54, 56, 69, 71, 94
 - glycinergic neurons, 95
 - glycinergic synapses, 90
 - glycine transporters. *see* Gly transporters (GLYT)
 - glycocholic acid, 122
 - glycosylation, 77, 109
 - GLYT. *see* Gly transporters (GLYT)
 - GLYT inhibitors, 92–94
 - GLYT1 inhibitors, 92–93
 - GLYT2 inhibitors, 93–94
 - therapeutic potential of, 94–95
 - Gly transporters (GLYT), 70, 90
 - inhibitors, 92–94
 - therapeutic potential of, 94–95
 - localization of, 90
 - molecular pharmacology of, 91–92
 - nomenclature of, 72
 - physiology of, 90–91
 - function of GLYT1 at excitatory synapses, 90–91
 - lessons from GLYT knockout mice, 91
 - subtypes, 73, 90

- gout, 113
 G protein-coupled receptors (GPCRs), 5
 GR. *see* glucocorticoid receptor (GR)
 guggulsterones, 211
 – *E*- and *Z*-, 209, 211
 GW4064 (7, FXR agonist), 203
 GW4064-related compounds, 216
- h**
- head and neck squamous cell carcinoma (HNSCC), 232
 hepatic cell, 199
 hepatic cholestasis, 201
 hepatic transporters, 207
 hepatobiliary transporters, 202
 – regulatory system of, 202
 hepatobiliary transport system, 200, 201, 202, 206
 hepatobiliary transport system by FXR
 – regulation of, 201
 hepatocyte nuclear factor (HNF), 136
 hepatocytes, 199, 204
 hepatotoxic effect, 203
 hereditary cholestatic syndromes, 200
 heterodimer complex FXR/RXR α , 201, 203
 heterogeneous group, of disease biologies, 24
 heteroreceptors, 41
 HGNC gene families, 5
 Hill coefficient, of calcium binding, 234
 hippocampus, 41, 42
 histamine, 41
 HIV protease inhibitors, 129
 HNF-1 α -binding elements, 207
 HNF-4 α homodimer, 206
 HNF-1 α ligand-independent transcription factor, 206
 homology modeling, 255
 – model building and assessment, 258
 – model refinement, 258
 – model validation, 258–259
 – target–template alignment, 258
 – template selection, 256–258
 hormone-responsive elements, 206
 H-symporter, 5
 5-HT_{1A} autoreceptor antagonist, 37
 5-HT_{1A} receptor
 – agonist, 37, 38
 – antagonism, 38
 – functional efficacy, 37
 5-HT_{1B} receptor, 41
 5-HT_{2C} receptor antagonist, 22
 5-HT_{1D} and 5-HT₇ receptor antagonism, 41
 5-HT levels, in brain, 26
 5-HT receptor modulating mechanisms, 25
 5-HT reuptake inhibitor, 27
 5-HT uptake, 31
 – and allosteric effect at human SERT and citalopram analogs, inhibition of, 29
 HUGO Gene Nomenclature Committee (HGNC), 6
 human ASBT transport protein, 207
 human membrane transport protein
 – classification of TCDB, IUPHAR/BPS, and ChEMBL-19 in contrast, 13
 – overview of, 9
 human P-glycoprotein, inhibitors of, 111
 human transport protein families, simplified overview of, 10
 hydrophathy analysis, 234
 hypercholesterolemia, 15
 6 Hz psychomotor seizure test, 86
- i**
- IBD. *see* inflammatory bowel disease (IBD)
 IL4, 232
 ileal bile acid-binding protein (IBABP), 201, 205, 219
 imipramine, 21, 24, 26, 29
 inflammatory bowel disease (IBD), 139
 inhibitory neurotransmitters, 70, 95
 – γ -aminobutyric acid (GABA), 70
 – glycine (Gly), 70
 inhibitory neurotransmitter transporters, 96
 International Union of Basic and Clinical Pharmacology (IUPHAR), 5
 intrahepatic cholestasis of pregnancy (ICP), 124, 127, 132
 ion channels, 5
 – proteins, 234
 – receptors, 70
 iproniazid, 21, 23
 isoxazole, 215, 216
 IUPHAR/BPS, 7
 – based classification, 12
 – level, 7
 IUPHAR/BPS Guide to PHARMACOLOGY, 5
 IUPHAR database, 5
 ivacaftor, 15, 108
 ivermectin, 214, 215
 Ixel[®], 32
- k**
- ketamine, 22
 kinase inhibitors, 107. *see also* Tyrosine kinase inhibitors
 kinases, catalytic receptors, 5

I

large neutral amino acid 1 transporter (LAT-1), 262
 LAT-1. *see* large neutral amino acid 1 transporter (LAT-1)
 LAT-1 substrates, 263
 – acivicin, 263
 – fenclonine, 263
 leucine transporter (LeuT), 27, 72
 – translocation pathway, 59
 LeuT. *see* leucine transporter (LeuT)
 LeuT-fold, 57
 levetiracetam, 10
 levomilnacipran, 32
 Lexapro[®], 26
 LG100268 (6, RXR agonist), 203
 ligand-activated FXR/RXR α , 205
 ligand-binding affinity, 260
 ligand-gated ion channels, 5
 ligand prediction
 – ligand selection, 260
 – virtual screening, 259–260
 – – models used for, 262
 lipid homeostasis, 133, 201
 lipophilic radioactive metabolites, 31
 lithogenicity, 132
 liver diseases, 127, 132, 138, 144, 200, 204, 217, 301, 303
 liver regeneration, 143, 201
 liver transporters, 199
 liver X receptor (LXR), 136
 LLC-PK1 MDR cells, 185
 LXR. *see* liver X receptor (LXR)

m

major depressive disorder (MDD), 21, 22, 24, 30, 32, 35, 38
 major facilitator superfamily (MFS), 5, 255, 258
 mammalian chloride channels, 232
 – mechanism of activation, 232, 233
 MAPK. *see* mitogen-activated protein kinase (MAPK)
Marine echoderms, 214
Marine sponges, 212
 marketing authorization (MA), 32
 maximal electroshock (MES), 86
 – test, 86
 Mdr1a/b^{-/-} mice, 186
 MDR3 (ABCB4) flippase protein, 204
 melatonin (MT)₁ and MT₂ receptor agonists, 22
 membrane depolarization, 231

membrane-inserted human SERT model, 57
 membrane transporters, 199
 membrane transport protein, 2, 4, 6, 7, 11, 12
 – databases, 2
 merged top-level transporter classification, 7–11
 MES. *see* maximal electroshock (MES)
 methylation of FXR at Lys206, 203
 N-methyl-D-aspartate receptors (NMDAR), 69
 midecamycin, 203
 milnacipran, 32
 milnacipran, 32
 mirtazepine, 22, 23
 mitogen-activated protein kinase (MAPK), 202, 237
 molecular docking, 259, 261
 molecular neuroscience, 53
 monoamine oxidase (MAO)-A and -B, 21
 monoamine oxidases, 24
 monoamine receptors, 37
 monoaminergic neurotransmitter levels, 24
 monoamines, 24
 – transporter inhibition, 22, 36
 monoamine transporters, 22, 24
 monoclonal antibodies, 107
 monotherapy, 30
 – UDCA, 142
 MRP2 (ABCC2) canalicular transporter, 203
 MRP4 expression, 204
 MRP2 gene, 203
 MRP4 gene
 – expression, 204
 MRPs. *see* multidrug resistance-associated proteins (MRPs)
 MRP4 (ABCC4) transporter, 204
 MT₂ receptor agonists, 22
 multidrug resistance-associated proteins (MRPs), 179
 multidrug resistance protein 1, 110
 multidrug resistance-related protein 1 (MRP1), 108
 multidrug-resistant tumor cells, 109
 multidrug transporters, 129
 multimodal antidepressants, 37
 – vortioxetine, 25
 multimodal drugs, 36
 – approach, 24
 multiple sequence alignments, 15
 multitarget drugs, 32, 33
 mutational studies at S1 site, 28

n

Na⁺-channels, 12
 NAGly. *see* *N*-arachidonyl-glycine (NAGly)
 Na⁺/H⁺ antiporters (SLC 9), 1
 Na⁺/K⁺ ATPases, 1
 (naphthalen-1-ylsulfanyl)acetonitrile, 30
 1-naphthyl and 1-indole derivatives, 30
 Na-symporter, 5
 nausea, 22
 NCor (nuclear corepressor), 207
 NE and 5-HT receptor modulator, 22
 neuroadaptive processes, 24
 neurogenesis, 24, 25, 41, 42
 neurological disorders
 – GABA-mediated synapses, role in, 85
 neuronal plasticity, 24, 25, 42
 neurotransmission, 40, 53, 69, 70, 79, 85
 – 5-HT, 41
 – NMDAR-mediated, 91
 – noradrenergic, 25
 – regional modulation, 40
 neurotransmitters, 21, 24, 69
 – γ -aminobutyric acid (GABA), 69
 – glycine (Gly), 69
 – monoamines dopamine, 69
 – norepinephrine, 69
 – serotonin, 69
 neurotransmitter:sodium symporter
 (NSS), 53, 255
 neurotransmitter systems, 24
 neurotransmitter transporters, 69, 256
 – binding site proper, 59–61
 – transport cycle, 61–63
 New Drug Application (NDA), 32
 Niemann-Pick C-1-like protein, 12
 γ -nitrogen, 78
 NMDA receptor antagonist, 22
 Nomenclature Committee of the International
 Union of Biochemistry and Molecular
 Biology, 2
 nonsteroidal compounds, 215
 – benzimidazole derivatives and retinoic
 acid-related compounds, 218, 219
 – fexaramine and derivatives, 217
 – FXR450 and derivatives, 217, 218
 – GW4064 and derivatives, 215–217
 – virtual screening campaigns, 219–221
 norepinephrine and dopamine reuptake
 inhibitors, 36
 norepinephrine reuptake inhibitors, 29
 – SNRIs, 22, 32
 norepinephrine transporter (NET), 21,
 256

NSS. *see* neurotransmitter:sodium symporter
 (NSS)
 NTCP. *see* taurocholate cotransporting
 polypeptide (NTCP)
 NTCP (sodium/taurocholic acid cotransporter
 protein), 206
 NTCP expression, 206
 nuclear hormone receptors (NHRs), 5
 nuclear localization, of FXR, 204
 nuclear receptors, 120, 205, 206
 – canonical structure of, 208
 – as drug targets, 140
 – PPAR α , 133
 – as regulators of BA metabolism, 121
 nucleotide binding domains (NBDs), 107, 108,
 122, 128, 132, 138

o

OATP-C gene, 204, 206
 OATP8 glycoprotein, 204
 obeticholic acid, 209
 obstructive cholestasis, 122, 125, 128, 130, 134,
 137, 138
 OCT1. *see* organic cation transporter 1 (OCT1)
 octyl-glucoside, 59
 oligopeptides, 204, 271
 Open PHACTS project, 11
 ophiuroids, 213
 organic anions, 206
 organic anion transporter proteins
 (OATPs), 204
 organic cation transporter 1 (OCT1), 253
 organic solute transporter alpha/beta
 (OST α /OST β), 199, 205
 oxidative stress, 125, 128, 309

p

pancreatic duct epithelial cells, 138
 paroxetine, 26
 PBC. *see* primary biliary cirrhosis (PBC)
 PC. *see* phosphatidylcholine (PC)
 peptide transporter
 – PEPT1, 259
 PET. *see* positron emission tomography (PET)
 PET tracers, 182, 184
 – chemical structures, 182
 P-glycoprotein (P-gp) inhibitors, 107
 – discovery of, 108
 – paradigm model system for, 110
 – physiological function of, 111
 – in vivo and in vitro concentration of, 100
 P-gp function, small-animal PET imaging
 of, 183

- P-gp inhibitor cyclosporine A, 185
 pharmacochaperone, 108
 pharmacokinetics, 129
 pharmacological characterization of FXR, 200
 pharmacological management, 200
 PHARMACOLOGY database, 5
 pharmacology-driven IUPHAR/BPS classification, 2
 phosphatidylcholine (PC), 132
 phosphatidylserine, 204
 phospholipid flippase (MDR3 or ABCB4), 200
 phospholipids, 204
 phosphorylation, 204
 phylogenetic heterogeneity, 10
 pindolol, 37
 PKC. *see* protein kinase C (PKC)
 placebo-controlled MDD study, 30
 pleiotropic activities, of FXR, 201
 PMRT-1 (protein arginine ("R") methyl transferase-1), 208
 polymorphisms, 129
 positron emission tomography (PET), 181
 postsynaptic receptors, 21, 53
 post-translational modification, 203
 post-translational phosphorylation, 204
 presynaptic inhibitory heteroreceptors, 40
 presynaptic neurons, 53
 primary biliary cirrhosis (PBC), 126, 200. *see also* cirrhosis
 primary sclerosis cholangitis (PSC), 200
 progesterone, 40
 progressive familial intrahepatic cholestasis (PFIC1-3), 200
 proinflammatory cytokines (IL-1 β , TNF α), 202
 proline, 59
 prophylactic therapy, 132
 protein composition, 199
 Protein Data Bank (PDB), 2
 protein kinase C (PKC), 27, 125
 proton pumps, 1
 protozoal channels, 2
 P-type ATPases, 5
 – protein, 200
- q**
- quality of life, 22
- r**
- radiolabelled BCRP substrates
 – [¹¹C]dantrolene, 189
 radiolabelled P-gp inhibitors
 – [¹¹C] labeled elacridar, 188
 – [¹¹C] labeled tariquidar, 187–188
 – [¹¹C] laniquidar, 189
 – [¹⁸F] labeled elacridar, 188
 – [¹⁸F] labeled tariquidar, 187–188
 radiolabelled P-gp substrates
 – [¹¹C] loperamide, 186–187
 – [¹¹C]-N-desmethyl-loperamide, 186–187
 – racemic [¹¹C]verapamil, 185–186
 – (R)-[¹¹C]verapami, 185–186
 radiolabelled transporter substrates, 181
 radiotracers, 181
 Raf kinase, 190
 R-citalopram, 26
 (R)- [¹¹C]verapamil
 – baseline scans, 186
 – metabolism, 186
 – transportation, 186
 refractory epilepsy, 180
 retinoic acid-related compounds, 218, 219
 reuptake blockers, 26
 Rh ammonium transporter family (SLC 42), 7
 Rh glycoproteins, 7
 rifampicin, 203
 rocking bundle model, 62
 RXR α (NR2B1) nuclear receptor, 206
- s**
- S1-binding pocket, 60
 scaffold domain, 62
Schisandra glaucescens diels, 212
 schizophrenia, 54, 94, 180
 – NMDAR hypofunction, role in, 94
 scPTZ. *see* subcutaneous pentylentetrazol (scPTZ)
 selective allosteric serotonin transporter modulator, 27
 selective bile acid receptor modulators (SBARMs), 212
 selective inhibitors, 95
 selective NE reuptake inhibitors, 31
 selective norepinephrine reuptake inhibitor, 30, 31
 selective serotonin reuptake inhibitors (SSRIs), 22, 26, 28
 S-enantiomer, 26
 serotonin
 – and dopamine reuptake inhibitors, 36
 – norepinephrine, and dopamine reuptake inhibitors, 33–35
 – and norepinephrine reuptake inhibitors, 32
 serotonin (5-HT) transporter (SERT), 21
 – inhibitor, 38
 – occupancy, 40
 sertraline, 26–28

- sexual dysfunction, 22
- SHP* and *BSEP* gene, 214
- SHP (NR0B2) atypical nuclear receptor, 205
- SHP structural properties, 205
- single-target drugs, 26
- Simularia*, 214
- SLC. *see* solute carrier transporters (SLC)
- SLC transporters
 - in cancer metabolism, 254
 - in cancer pathogenesis, 253
 - counterparts in TCDB, 7
 - in drug absorption, disposition, metabolism and excretion (ADME), 253
 - members counterparts in TCDB, 6
 - pseudosymmetry of, 259
 - series, 6, 7
- SLC6-transporters, 62
 - crystal structures, 55–59
 - involvement in health and disease, 54
 - substrate-binding site, 61
- small heterodimer partner (SHP), 201
- sodium-dependent transporter (NTCP or SLC10A1), 199
- sodium-independent large organic anion transporters (SLCO), 107
- sodium-independent organic anion transporters (OATPs or SLC21A), 199
- sodium-potassium ATPase, 61
- solute carrier class (SLC), 107
- solute carrier 6 family (SLC6) neurotransmitter transporter, 53
- solute carriers, 69
 - superfamily 6 of, (SLC6), 69
- solute carrier transporters (SLC), 253
- somatodendritic autoreceptors, 41
- sorafenib, 180, 190
- soy lipids, 214
- spare transporter effect, 183
- SRC-1 (steroid receptor coactivator 1), 207
- SSRI antidepressants, 26
- SSRI citalopram, 29
- STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trials, 22
- steroid-binding pocket, 209
- steroids, 205
- Stratera[®], 30
- stroke, GAT, therapeutic potential in, 89
- structural modifications of bile acid scaffold, 209
- structure–activity relationship (SAR) studies, 214
- structure-based ligand discovery
 - computational methods used in, 264
 - structure of INT-747 derivatives
 - and activities (EC50) at FXR receptor, 209
 - subcutaneous pentyletetrozol (scPTZ), 86
 - test, 86
 - substantial medicinal chemistry, 200
 - substrate-like behavior, 183
 - substrate transport
 - transporter-mediated, 70–71
 - subtype-selective inhibitors, 74
 - sulfated polyhydroxysterols, 213
 - synapses
 - GABAergic and glycinergic
 - – inhibitory neurotransmission at, 70
 - synaptic cleft, 53
 - synaptic transmission, 70
 - synaptosomal vesicle fusion pore (SVF-Pore) family, 12
- t**
- talopram, 29
- Tangier disease, 113
- tauro-CA, 203
- tauro-CDCA, 203
- taurocholate cotransporting polypeptide (NTCP), 120
- TCDB class 1, 2, 4, and 8, 7
- theonellasterol G, 214
- Theonella swinhoei*, 213, 214
- therapeutic approaches, 24
- therapy-refractory epilepsy, 184
- thermal hyperalgesia, 95
- threonine, 204
- tiagabine, 74, 78, 85, 87, 89
 - epilepsy, efficacy of, 87
- TM. *see* transmembrane (TM)
- TMEM16A. *see* transmembrane protein with unknown function 16 (TMEM16A)
- topotecan, 189
- total parenteral nutrition (TPN), 122
- TPN. *see* total parenteral nutrition (TPN)
- transcriptional activity, 204, 206
- transcriptional factors, 207
- transcriptional inhibitors, 206
- transmembrane (TM), 72
 - domains (TMDs), 108
 - helices, 56
 - sodium gradient, 53, 61
 - transport activity, 11
- transmembrane protein with unknown function 16 (TMEM16A), 233
- transporter as drug targets, 12
- Transporter Classification Database (TCDB), 2, 4

- transporter classification system, 2
- transporter collections
- with a focus on human membrane transport proteins, 3
- transporter family, 4
- transporter-overexpressing cell lines, 188
- transporter proteins, 55
- transporters, 2, 4, 5, 11, 12, 15
- heterogeneity of, 95
- transporter-selective radiotracers, 183
- PET radiotracer, 184
- transport proteins, 11, 199
- transport system 2.A.22.6.3
- as an example of the TCDB classification, 4
- tricyclic antidepressant (TCA), 21
- triglycerides, 201
- Trintellix[®], 38
- triterpenes, 212
- troglitazone, 203
- tryptophan, 59
- tumor development, multiple amino acid transporters in, 264
- tumorigenesis, 201
- tumor therapy, 107
- tyrosine kinase inhibitors, 180, 190
- cancer treatment, role in, 180
- tyrosine transporters, 55
- u**
- UDCA. *see* ursodeoxycholic acid treatment (UDCA)
- unconjugated hyperbilirubinemia, 285
- uniprot, 5, 15
- UniProt accession number, 4
- ursodeoxycholic acid treatment (UDCA)
- in cholestatic liver disease, 144
- US Food and Drug Administration (FDA), 30
- black box warning on atomoxetine, 30
- v**
- van der Waals interactions, 210
- vascular reactivity, 201
- VDR. *see* vitamin D receptor (VDR)
- venlafaxine, 32
- vesicular transporters, 62
- vilazodone, 37, 38
- vincristine, 109, 129
- vitamin D receptor (VDR), 122
- voltage-gated ion channels, 5
- vortioxetine (Lu AA21004), 38, 39, 40, 42
- antidepressant and anxiolytic properties, 40
 - 5-HT₃ receptor antagonism, 41
 - increases DA in prefrontal cortex, 41
 - originally designed to increase 5-HT neurotransmission, 41
 - receptor activities result in different modulation, 41
 - target occupancy, dose relations determined by, 40
 - in vitro binding affinities and functional efficacy of, 39
- VX-661 and VX-809, chemical structure, 114
- x**
- xenobiotics, 133, 204
- y**
- yeast transport protein database, 2
- z**
- zinc binding site, 58

